Related references
Note: Only part of the references are listed.Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials
A. Wollenberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro
Pernille M. Hansen et al.
ALLERGY (2022)
Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis
Maria C. Schneeweiss et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Risk of systemic infections in adults with atopic dermatitis: A nationwide cohort study
Catherine Droitcourt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial
J. I. Silverberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
A. Wollenberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity scoreematched cohort study
Maria C. Schneeweiss et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Atopic eczema in adulthood and mortality: UK population-based cohort study, 1998-2016
Richard J. Silverwood et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
Joseph F. Merola et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the UK and the USA
L. Andersen et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation
M. Augustin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial
Emma Guttman-Yassky et al.
JAMA DERMATOLOGY (2020)
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
Jonathan Silverberg et al.
JAMA DERMATOLOGY (2020)
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children
A. Wollenberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb
Andreas Wollenberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
Lawrence F. Eichenfield et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Conjunctivitis in dupilumab clinical trials
B. Akinlade et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis A Phase 2 Randomized Clinical Trial
Melinda J. Gooderham et al.
JAMA DERMATOLOGY (2019)
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma
William W. Busse et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis
Lam C. Tsoi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Cause-specific mortality in adults with atopic dermatitis
Jacob P. Thyssen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: partII
A. Wollenberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
Reynold A. Panettieri et al.
LANCET RESPIRATORY MEDICINE (2018)
Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
Patrick M. Brunner et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2
B. Popovic et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt et al.
LANCET (2017)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Maurizio Mennini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies
Mark Boguniewicz et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2017)
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies
Christy Chuang-Stein et al.
PHARMACEUTICAL STATISTICS (2011)
Viral infections in atopic dermatitis: Pathogenic aspects and clinical management
A Wollenberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)